Please use this identifier to cite or link to this item: http://repository.tma.uz/xmlui/handle/1/2513
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZufarov P.S., Saidova Sh.A., Akbarova D.S., Musaeva L.J, Pulatova D.B., Abdumajidova N.H-
dc.date.accessioned2022-10-07T06:10:29Z-
dc.date.available2022-10-07T06:10:29Z-
dc.date.issued2022-
dc.identifier.urihttp://repository.tma.uz/xmlui/handle/1/2513-
dc.description.abstract50 patients aged from 35 to 67 years inclusive with the diagnosis of BA were included in the study. The patients were divided into 2 groups by random sampling. Patients of the first group (control group) -25 people received basic therapy with inhaled glucocorticosteroids and long-acting p2-agonists in the form of combined preparation of Seretide 25/250 meg or 25/500 meg 2 times daily. Patients of the second group -25 people received 25/250 or 50/250 meg Seretide twice a day, and also leukotriene receptor inhibitor Montiget in a dose of 10 mg once dailyen_US
dc.language.isoenen_US
dc.publisherToshkenten_US
dc.subjectExperience of using montiget, moderate to severe courseen_US
dc.titleExperience of using montiget in patients with bronchial asthma of moderate to severe courseen_US
dc.typeThesisen_US
Appears in Collections:Thesis, Articles

Files in This Item:
File Description SizeFormat 
5.pdfExperience of using montiget in patients with bronchial asthma of moderate to severe course199.35 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.